Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cetrelimab + erdafitinib
- Development stage
- Phase 2
- Lead developer
- Janssen Research & Development
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Cetrelimab + erdafitinib is a combination therapy under investigation for the treatment of advanced or metastatic urothelial carcinoma and other solid tumors. Cetrelimab is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1), acting as an immune checkpoint inhibitor to enhance anti-tumor immune responses. Erdafitinib is an orally administered small molecule that acts as a potent and selective pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, targeting FGFR1, FGFR2, FGFR3, and FGFR4. This combination aims to leverage both direct inhibition of tumor growth via FGFR blockade and stimulation of anti-tumor immunity through PD-1 inhibition. The combination has shown manageable safety in early-phase clinical trials and demonstrated improved efficacy over monotherapy in phase 2 studies for metastatic urothelial carcinoma with susceptible FGFR genetic alterations[5][8].
- Other names
- cetrelimab + erdafitinib
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)PDCD1 (Programmed cell death protein 1 receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on cetrelimab + erdafitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cetrelimab + erdafitinib.